ES2152412T3 - Preparacion farmaceuticamente estable de oxaliplatino. - Google Patents

Preparacion farmaceuticamente estable de oxaliplatino.

Info

Publication number
ES2152412T3
ES2152412T3 ES95925976T ES95925976T ES2152412T3 ES 2152412 T3 ES2152412 T3 ES 2152412T3 ES 95925976 T ES95925976 T ES 95925976T ES 95925976 T ES95925976 T ES 95925976T ES 2152412 T3 ES2152412 T3 ES 2152412T3
Authority
ES
Spain
Prior art keywords
pct
oxaliplatinum
oxaliplatino
pharmaceutically stable
stable preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95925976T
Other languages
English (en)
Inventor
Houssam Ibrahim
Rolland-Yves Mauvernay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debiopharm SA
Original Assignee
Debiopharm SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50845249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2152412(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debiopharm SA filed Critical Debiopharm SA
Application granted granted Critical
Publication of ES2152412T3 publication Critical patent/ES2152412T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

ESTA INVENCION SE REFIERE A UNA PREPARACION FARMACEUTICAMENTE ESTABLE DE OXALIPLATINO PARA ADMINISTRACION POR VIA PARENTERAL, QUE ESTA CONSTITUIDA POR UNA SOLUCION OXALIPLATINO EN AGUA EN UNA CONCENTRACION DE 1 A 5 MG/ML, CUYO PH ES DE 4,5 A 6. ESTA SOLUCION ACUOSA DE OXALIPLATINO SE PRESENTA VENTAJOSAMENTE EN FORMA DE UNA PREPARACION LISTA PARA USAR QUE ESTA CONTENIDA EN UN RECIPIENTE HERMETICAMENTE CERRADO.
ES95925976T 1994-08-08 1995-08-07 Preparacion farmaceuticamente estable de oxaliplatino. Expired - Lifetime ES2152412T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH246294 1994-08-08

Publications (1)

Publication Number Publication Date
ES2152412T3 true ES2152412T3 (es) 2001-02-01

Family

ID=50845249

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95925976T Expired - Lifetime ES2152412T3 (es) 1994-08-08 1995-08-07 Preparacion farmaceuticamente estable de oxaliplatino.

Country Status (17)

Country Link
US (1) US5716988A (es)
EP (1) EP0774963B1 (es)
JP (1) JP3547755B2 (es)
KR (1) KR100365171B1 (es)
CN (1) CN1138541C (es)
AT (1) ATE197249T1 (es)
AU (2) AU2989695A (es)
BR (1) BR9508554A (es)
CA (1) CA2196922C (es)
CZ (1) CZ286714B6 (es)
DE (1) DE69519300T2 (es)
DK (1) DK0774963T3 (es)
ES (1) ES2152412T3 (es)
IL (1) IL114852A (es)
RU (1) RU2148400C1 (es)
UA (1) UA42779C2 (es)
WO (1) WO1996004904A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519300T2 (de) 1994-08-08 2001-05-31 Debiopharm Sa Stabiles arzneimittel enthaltend oxaliplatin
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations
WO2000021527A2 (fr) * 1998-10-14 2000-04-20 Debiopharm S.A. Conditionnement d'une preparation d'oxaliplatine
GB9904386D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
BRPI0013613B8 (pt) * 1999-08-30 2021-05-25 Debiopharm Sa composição farmacêuticamente estável de oxaliplatina para administração parenteral.
US7070796B1 (en) * 1999-08-30 2006-07-04 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation for parenteral administration
US7012072B2 (en) * 2000-12-12 2006-03-14 Debiopharm S.A. Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same
SI1368022T1 (sl) * 2001-03-02 2007-10-31 Debiopharm Sa Uporaba stekleničke, ki vsebuje raztopino oksaliplatina
EP1404689A1 (en) * 2001-07-02 2004-04-07 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
CA2388352A1 (en) * 2002-05-31 2003-11-30 Voiceage Corporation A method and device for frequency-selective pitch enhancement of synthesized speed
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
JP2007504098A (ja) 2003-08-28 2007-03-01 メイン・ファーマ・リミテッド 酸を含むオキサリプラチン製剤
EP2330110A1 (en) 2003-11-25 2011-06-08 Platco Technologies (Proprietary) Limited Platinum(II) complexes, preparation and use
CN100471493C (zh) * 2003-12-17 2009-03-25 梅比欧法姆股份有限公司 含有奥沙利铂的脂质体制剂
JP5578753B2 (ja) * 2004-06-09 2014-08-27 大鵬薬品工業株式会社 抗腫瘍効果増強剤、抗腫瘍剤及び癌治療方法
ES2327346T3 (es) 2004-09-01 2009-10-28 Platco Technologies (Proprietary) Limited Preparacion de complejos de platino (ii).
US20060063720A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Oxaliplatin solution concentrate
US20060063833A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Ready-to-use oxaliplatin solutions
DE102004052877B4 (de) * 2004-11-02 2008-06-19 Ebewe Pharma Ges.M.B.H. Nfg.Kg Stabile wässrige Formulierungen eines Platin-Derivats
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2007029268A2 (en) 2005-09-05 2007-03-15 Dabur Pharma Limited Stable oxaliplatin formulation
US7956208B2 (en) * 2006-01-30 2011-06-07 Platco Technologies (Proprietary) Limited Preparation of platinum (II) complexes
CA2647297A1 (en) * 2006-03-16 2007-09-27 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
JP2009536180A (ja) 2006-05-09 2009-10-08 ノバルティス アクチエンゲゼルシャフト 鉄キレート剤と抗新生物剤を含む組合せ剤およびそれらの使用
PT2101805E (pt) * 2007-01-18 2013-01-31 Merck Patent Gmbh Terapia específica e medicamento usando ligandos integrina para tratar o cancro
US20090076139A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched oxalplatin
US20100267824A1 (en) * 2007-11-12 2010-10-21 Intas Pharmaceuticals Limited Stable oxaliplatin composition for parenteral administration
JP5694782B2 (ja) 2008-03-14 2015-04-01 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 肺癌、腺癌及び他の病状のための治療方法及び組成物
WO2009113989A1 (en) 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
JP5759464B2 (ja) 2009-09-21 2015-08-05 ジェイダブリュー ファーマシューティカル コーポレイション オキサリプラチンのナノ粒子及びその製造方法
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
AU2013202575B1 (en) * 2012-01-04 2013-05-16 Hospira, Inc. Dexmedetomidine premix formulation
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
JP5314790B1 (ja) * 2012-07-09 2013-10-16 東和薬品株式会社 オキサリプラチン含有医薬組成物
ES2733061T3 (es) 2012-08-10 2019-11-27 Taiho Pharmaceutical Co Ltd Dispersión acuosa de liposomas encapsulantes de oxaliplatino estable y método para estabilización de la misma
KR102238677B1 (ko) 2012-09-07 2021-04-12 코히러스 바이오사이언시즈, 인코포레이티드 아달리무맙의 안정한 수성 제형
CN103690494B (zh) * 2013-11-29 2015-04-15 杭州华东医药集团新药研究院有限公司 一种低杂质含有奥沙利铂的组合物及其制备方法
BR112016030310A2 (pt) 2014-06-23 2017-08-22 Placon Therapeutics Inc Compostos de platina, composições e seus usos
AU2016289856B2 (en) 2015-07-07 2020-11-26 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
CN104940151A (zh) * 2015-07-23 2015-09-30 青岛蓝盛洋医药生物科技有限责任公司 一种抗癌药物奥沙利铂冻干粉针剂组合物
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
WO2017192290A1 (en) 2016-05-04 2017-11-09 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and platinum-based antineoplastic drugs
EP3481398A1 (en) 2016-07-06 2019-05-15 Imara, Inc. Pde9 inhibitors for treatment of peripheral diseases
HRP20240146T1 (hr) 2017-05-26 2024-04-12 Cardurion Pharmaceuticals, Inc. Postupci dobivanja i upotrebe inhibitora pde9
SI3801526T1 (sl) 2018-05-25 2024-05-31 Cardurion Pharmaceuticals, Inc. Monohidratne in kristalinične oblike 6-((3s, 4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il)-3-tetrahidropiran-4- il-7h-imidazo (1.5 - a) pirazin-8-ona

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) * 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
IL83380A (en) * 1987-07-30 1991-04-15 Teva Pharma Stable aqueous cisplatin solutions
NL8901433A (nl) * 1989-06-06 1991-01-02 Pharmachemie Bv Carboplatinpreparaat.
JPH04185601A (ja) * 1990-11-20 1992-07-02 Unitika Ltd 白金抗癌剤徐放性製剤
JP2673331B2 (ja) * 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
AU5416394A (en) * 1992-11-24 1994-06-22 Debiopharm S.A. Cisplatinum/oxaliplatinum combination
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
DE69519300T2 (de) 1994-08-08 2001-05-31 Debiopharm Sa Stabiles arzneimittel enthaltend oxaliplatin

Also Published As

Publication number Publication date
UA42779C2 (uk) 2001-11-15
BR9508554A (pt) 1997-11-25
WO1996004904A1 (fr) 1996-02-22
US5716988A (en) 1998-02-10
IL114852A0 (en) 1995-12-08
EP0774963A1 (fr) 1997-05-28
CN1154654A (zh) 1997-07-16
EP0774963B1 (fr) 2000-11-02
CN1138541C (zh) 2004-02-18
ATE197249T1 (de) 2000-11-15
KR100365171B1 (ko) 2003-02-19
CZ286714B6 (en) 2000-06-14
CA2196922C (fr) 2004-06-01
AU731981B2 (en) 2001-04-12
JPH10508289A (ja) 1998-08-18
KR970704434A (ko) 1997-09-06
RU2148400C1 (ru) 2000-05-10
DE69519300D1 (de) 2000-12-07
CZ37997A3 (en) 1997-06-11
JP3547755B2 (ja) 2004-07-28
DK0774963T3 (da) 2001-01-29
AU2252499A (en) 2000-03-23
CA2196922A1 (fr) 1996-02-22
AU2989695A (en) 2000-03-07
IL114852A (en) 2000-02-29
DE69519300T2 (de) 2001-05-31

Similar Documents

Publication Publication Date Title
ES2152412T3 (es) Preparacion farmaceuticamente estable de oxaliplatino.
PL325825A1 (en) Microemulsion for use as a carrier for administering active compounds
RU94040387A (ru) Композиция, способствующая прекращению курения, никотиносодержащий распыляемый раствор, способ снижения потребности в курении табака, способ замены курения табака
PT1251750E (pt) Formula pediatrica melhorada e metodos para proporcionar nutricao e melhorar a tolerancia
NO20054324L (no) Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning
AU2001288460A1 (en) Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
KR920007629A (ko) SALMe염, 5-MTHF 및 5-FTHF 중에서 선택된 화합물 적어도 1개를 유효성분으로서 함유하여 AIDS환자의 신경학적 질환치료시 활성을 나타내는 약제학적 조성물
NZ505821A (en) Pharmaceutical compositions of uridine triphosphate
HK1040088A1 (en) Echinocandin/carbohydrate complexes
HK1046090A1 (en) Use of l-carnitine and its alkanoyl derivatives asosmotic agents in solutions for medical use
ATE350024T1 (de) Flüssige zubereitung enthaltend tobramycin
AU1852597A (en) Multifunctional fat absorption and blood cholesterol reducing formulation containing chitosan and nicotinic acid
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
EE04264B1 (et) Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks
AU2001289762A1 (en) Pharmaceutical extemporary compositions
ATE203903T1 (de) Delta-aminolävulinsäure enthaltendes arzneimittel
HK1036413A1 (en) Solution comprising prostaglandins and benzyl alcohol.
Lin et al. Toxicity of a single oral dose of N-ethylphenylacetamide in rats
SE9700617D0 (sv) New composition
MX9708195A (es) Formulaciones para compuestos lipofilicos y uso de las mismas.
MY104837A (en) Injectable ready-to-use solutions containing an antitumor anthracycline glycoside

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 774963

Country of ref document: ES